tracken
Neurocrine Biosciences, Inc. Aktie News
Neutral
PRNewsWire
●
etwa 12 Stunden alt
WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share experiences and learn about current research.
Positiv
InvestorPlace
●
etwa 13 Stunden alt
The economy is currently on a stable trajectory and is poised for sustained growth; the indicators show a positive outlook overall. However, the biotech industry presents even more compelling potential, demonstrating a compounding annual growth rate (CAGR) of 13.96% from 2024 to 2030.
Positiv
Investors Business Daily
●
ein Tag alt
Top-notch biotech stock Neurocrine launched higher Tuesday after the company's depression treatment succeeded in a midstage study.
Neutral
PRNewsWire
●
ein Tag alt
SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statistically Significant Reduction in MADRS Score at Day 56 NBI-1065845 Was Generally Well-Tolerated SAN DIEGO , April 23, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced...
Neutral
GlobeNewsWire
●
9 Tage alt
Tokyo, Japan and Cambridge, UK, 16 April 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – has been notified by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX) that NBI-1117568, an oral selective muscarinic M4 receptor agonist being advanced in Phase 2 clinical trials by Neurocrine for the treatment of schi...
Neutral
PRNewsWire
●
14 Tage alt
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 1 SAN DIEGO , April 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m.
Neutral
PRNewsWire
●
22 Tage alt
SAN DIEGO , April 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder. NBI-1070770 is a novel, selective, and orally active, negative allosteric modulator (NAM...
Positiv
Investors Business Daily
●
23 Tage alt
As shares of Meta and Nvidia stock hold near highs, Uber, CyberArk and four other growth stocks set up bases and buy zones.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
